Research programme: psychedelic-derived therapeutics - Clearmind Medicine/Hebrew University of Jerusalem
Latest Information Update: 19 Sep 2024
At a glance
- Originator Clearmind Medicine; Hebrew University of Jerusalem
- Class Antipsychotics
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alcoholism
Most Recent Events
- 12 Sep 2024 Clearmind Medicine and Yissum files for patent protection under the International Patent Cooperation Treaty (PCT) for Psychedelic-derived therapeutics
- 07 May 2024 Clearmind Medicine and Yissum Research Development company agree to co-develop psychedelic-derived therapeutics for Post-traumatic stress disorder
- 21 Sep 2021 Clearmind Medicine and the Hebrew University of Jerusalem agree to co-develop psychedelic-derived therapeutics for Alcoholism